Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.57 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.57 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.57 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.57 |
| ▸ | PER2 | O15055 | 7/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13293935 | 0.82 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8282939 | 0.81 | CHRM2 (0.60) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4330615 | 0.79 | CHRM2 (0.49) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7621988 | 0.77 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4338414 | 0.77 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5331770 | 0.77 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL29286050 | 0.76 | ACE (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL1869119 | 0.76 | MEN1 (0.48) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7643090 | 0.74 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL4681916 | 0.74 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518189-B2 | Binder solutions | THE CHEMOURS COMPANY FC, LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140378584-A1 | BINDER SOLUTIONS | THE CHEMOURS COMPANY FC, LLC | 2014-12-25 | — | — | US | disclosed |
| EP-2802634-A1 | BINDER SOLUTIONS | E. I. Du Pont de Nemours and Company (US) | 2014-11-19 | — | — | EP | disclosed |
| US-8721770-B2 | Carbon dioxide removal and ionic liquid compounds useful therein | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8721770-B2 | Carbon dioxide removal and ionic liquid compounds useful therein | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| US-8721770-B2 | Carbon dioxide removal and ionic liquid compounds useful therein | E I DU PONT DE NEMOURS AND COMPANY (US) | 2014-05-13 | — | — | US | disclosed |
| WO-2013106421-A1 | BINDER SOLUTIONS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-8350056-B2 | Functionalized N-substituted pyrrolidonium ionic liquids | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350056-B2 | Functionalized N-substituted pyrrolidonium ionic liquids | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350056-B2 | Functionalized N-substituted pyrrolidonium ionic liquids | E I DU PONT DE NEMOURS AND COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-7314962-B2 | Alkylation of aromatic compounds | E. I. DU PONT DE NEMOURS & CO. (US) | 2008-01-01 | — | — | US | disclosed |
| US-20070123737-A1 | Preparation of polytrimethylene ether glycol and copolymers thereof | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-05-31 | — | — | US | disclosed |
| WO-2007050490-A2 | OLEFIN ISOMERIZATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070100192-A1 | Olefin isomerization | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-05-03 | — | — | US | disclosed |
| WO-2007038362-A1 | PREPARATION OF POLYTRIMETHYLENE ETHER GLYCOL AND COPOLYMERS THEREOF | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070066853-A1 | Preparation of poly(tetramethylene) glycol | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066834-A1 | Ionic liquids | E. I. DU PONT DE NEMOURS AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7157588-B2 | Ionic liquids | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20060235230-A1 | Based on an N-substituted pyrrolidinone having a pendant ammonium cation that is separated from the pyrrolidone ring by a variable length alkyl spacer; use as solvents, catalysts; can be readily prepared from levulinic acid or derivatives obtained from the hydrolysis of inexpensive biomass feedstock | THE CHEMOURS COMPANY FC, LLC | 2006-10-19 | — | — | US | disclosed |
| US-20060235249-A1 | Alkylation of aromatic compounds | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066853-A1 | Preparation of poly(tetramethylene) glycol | PARG, PUF60, TPR | CHRM2 4672/4885CHRM4 4575/4885CHRM5 3941/4885 |
| US-20070066834-A1 | Ionic liquids | NUP205, PML, AQP4 | CHRM2 4192/4885CHRM4 4264/4885CHRM5 3308/4885 |
| US-20070123737-A1 | Preparation of polytrimethylene ether glycol and copolymers thereof | PARG, PTGES3, PGD | CHRM2 3146/4885CHRM4 3594/4885CHRM5 3264/4885 |
| US-20060235249-A1 | Alkylation of aromatic compounds | TYR, ALK, AHR | CHRM2 1525/4885CHRM4 752/4885CHRM5 941/4885 |
| US-20060235230-A1 | Based on an N-substituted pyrrolidinone having a pendant ammonium cation that is separated from the pyrrolidone ring by a variable length alkyl spacer; use as solvents, catalysts; can be readily prepared from levulinic acid or derivatives obtained from the hydrolysis of inexpensive biomass feedstock | ALAD, ASS1, ADSL | CHRM2 3911/4885CHRM4 4063/4885CHRM5 2812/4885 |
| US-20070100192-A1 | Olefin isomerization | OSBP, OXER1, OSBPL3 | CHRM2 3157/4885CHRM4 2323/4885CHRM5 3238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.